First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
一线治疗晚期非小细胞肺癌，比较纳武利尤单抗联合伊匹木单抗加两周期化疗与单纯化疗（四周期）的疗效：CheckMate 9LA 两年更新研究
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100273
Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, T
